Current Studies

Please click the trial name for more information.

Prostate Cancer

We offer clinical trials for patients newly diagnosed with prostate cancer and those who have received prior treatments as well. If you fall under one of these categories, please click on the studies below to learn more. Each trial is associated with a National Clinical Trial (NCT) number which links to ClinicalTrials.gov for more information about the study, sponsor, and criteria. All study related medications and tests are covered by Research.

New Diagnosis

Prostate Cancer Treatment (NCT06235151)

Summary: Diagnostic imaging trial to test the diagnostic performance of Cu-64 PSMA PET scan
in patients with newly diagnosed prostate cancer at unfavorable intermediate, high, and very high-risk levels.

Requirements for participation:

  • Male ≥18 years of age at the time of signing the informed consent
  • Newly diagnosed with prostate cancer

Not eligible if any of the following apply:

  • Received prior treatments/therapies for prostate cancer
  • Taken a PSMA-PET scan within 90 days of study enrollment

Biochemical Recurrence (BCR)

Prostate Cancer Treatment (NCT05059236)

Summary: Phase 3 study of Darolutamide(Nubeqa) and ADT or ADT alone for the treatment for high-risk biochemical
recurrent prostate cancer in patients that have received initial treatment for their cancer (i.e.Prostatectomy
(removal of prostate), prostatectomy and radiation, or radiation alone)

Requirements for participation:

  • High risk bio-chemical recurrence (BCR), defined by rising PSA levels
  • Must be able to receive MRI, CT, or PSMA PET/CT imaging

Not eligible if any of the following apply: 

  • Other cancer diagnosis
  • History of Orchiectomy

Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

Prostate Cancer Treatment (NCT06120491)

Summary: Phase 3 study with second generation PARP inhibitor AZD5305 (Saruparib) in combination with second generation
anti-androgens for patients with newly diagnosed or recurrent metastatic castrate sensitive prostate cancer.

Requirements for participation:

  • Metastatic prostate cancer
  • Ongoing treatment withandrogen depravation therapies

Not eligible if any of the following apply:

  • History of other primary malignancies
  • Previous treatment with PARP inhibitors, second generation anti-androgen therapies, anti-cancer therapies for metastatic prostate cancer

Prostate Cancer Treatment (NCT06991556 )

Summary:Randomized study for metastatic castrate sensitive prostate cancer (mCSPC) with study drug JSB462 in combination with abiraterone vs physician choice (abiraterone/enzalutamide).

Requirements for participation:

  • Metastatic Castrate/Hormone Sensitive Prostate Cancer diagnosis (mCSPC)
  • Naïve to second generation ARPI treatment (abiraterone, enzalutamide
  • PSA > 0.2

Not eligible if any of the following apply:

  • No metastasis
  • Other primary malignancies

Metastatic Castrate Resistant Prostate Cancer (mCRPC)

Prostate Cancer Treatment (NCT06551324)

Summary: Phase 3 study for patients with metastatic castrate resistant prostate cancer with Mevrometostatin combination with Enzalutamide or Enzalutamide alone

Requirements for participation:

  • Failed treatment with Abiraterone Acetate (Zytiga, Yonsa)
  • Rise in PSA and metastasis

Not eligible if any of the following apply:

  • Prior chemotherapy or second-generation anti-cancer therapies

Prostate Cancer Treatment (NCT06629779)

Summary: Phase 3 study for patients with metastatic castrate resistant prostate cancer with study drug Mevrometostat in combination with Enzalutamide. This study is for patients who have never taken novel hormone therapy (NHA) or chemotherapy but have failed treatment with androgen deprivation therapy (ADT).

Requirements for participation:

  • Failed treatment with androgen deprivation therapy (ADT).
  • Rise in PSA and metastasis

Not eligible if any of the following apply:

  • Prior chemotherapy or second-generation anti-cancer therapies (NHA)

Prostate Cancer Treatment (NCT07047118)

Summary: Phase 2 randomized study of study drug JSB462 – Luxdegalutamide in combination with 177Lu Lutetium Vipivotide
Tetraxetan for patients showing PSMA-positive metastatic castrate resistant prostate cancer (mCRPC).

Requirements for participation:

  • Prior exposure to at least 1 second generation ARPI treatment
  • PSMA positive lesions on scans
  • No prior treatment with Radio Ligand Therapy (RLT)
  • mCRPC diagnosis

Not eligible if any of the following apply:

  • No metastasis
  • Other primary malignancy
  • Severe cardiac medical history

Non-Metastatic Castration-Sensitive Prostate Cancer (nmCSPC)

Prostate Cancer Treatment (NCT06952803)

Summary: Randomized placebo-controlled study of Saruparib for patients with the BRACAm mutation who have localized high-risk prostate cancer and have received primary radiation therapy or radical prostatectomy.

Requirements for participation:

  • Non-metastatic prostate cancer or Biochemical Recurrence
  • BRACAm+
  • High-risk localized prostate cancer
  • Ongoing Androgen Deprivation Therapy (ADT)

Not eligible if any of the following apply:

  • Prior chemotherapy, immunotherapy, or PARP inhibitor treatment
  • Other primary malignancies
  • No BRACA mutations

Bladder Cancer

We offer clinical trials for patients newly diagnosed with bladder cancer and those who have received prior treatments as well. If you fall under one of these categories, please click on the studies below to learn more. Each trial is associated with a National Clinical Trial (NCT) number which links to ClinicalTrials.gov for more information about the study, sponsor, and criteria. All study related medications and tests are covered by Research.

Non-Muscle Invasive Bladder Cancer (NMIBC)

Bladder Cancer Treatment (NCT06111235)

Summary: Phase 3 study of Cretostimogene Grenadenorepvec versus observation in patients with Intermediate-risk non-muscle invasive bladder Cancer who have had transurethral resection of bladder tumor (TURBT). The study aims to observe and evaluate recurrence free survival.

Requirements for participation: 

  • Transurethral resection of bladder tumor (TURBT) within 12 weeks of starting study

Not eligible if any of the following apply:

  • History of Carcinoma in situ (CIS)
  • History of high-risk non-muscle invasive bladder cancer

Bladder Cancer Treatment (NCT02138734)

Summary: Phase 2b study of Bacillus Calmette-Guerin (BCG) and N-803 for patients with Non-Muscle Invasive Bladder Cancer who have NEVER had BCG treatment. The study involves randomization into treatment with N-803 + BCG or BCG only.

Requirements for participation:

  • Non-Muscle invasive bladder cancer with high grade carcinoma/ papillary disease
  • Carcinoma in-situ (CIS) histology
  • Eligible for BCG treatment

Not eligible if any of the following apply:

  • Had previous BCG treatment
  • History of muscle invasive bladder cancer

Bladder Cancer Treatment (NCT06567743)

Summary: Phase 2 study of Cretostimogene Grenadenorepvec and DDM in patients with high-risk Non-Muscle Invasive Bladder Cancer who are BCG naïve or exposed. 

Requirements for participation:

  • Non-muscle invasive bladder cancer
  • CIS or No CIS histology

Not eligible if any of the following apply:

  • Unable to resect all disease before treatment
  • History of muscle invasive bladder cancer
  • Prior organ transplant

Bladder Cancer Treatment (NCT06443944 )

Summary: Expanded access program study for patients who are unresponsive to BCG and present with high-risk CIS pathology. The study offers bladder instillations with Cretostimogene Grenadenorepvec oncolytic immunotherapy.

Requirements for participation:

  • Past treatment with BCG (Induction + maintenance)
  • High risk CIS pathology
  • Non-muscle invasive bladder cancer (NMIBC)

Not eligible if any of the following apply:

  • Incomplete prior BCG treatment
  • History of Muscle invasive bladder cancer (MIBC)
  • Prior systemic/radiation treatments for bladder cancer

Bladder Cancer Biomarker Study

Bladder Cancer Biomarker Study

Summary: Non-invasive urine URO17 Bladder Cancer biomarker detection study in patients presenting gross and microscopic hematuria with suspected bladder cancer.

Requirements for participation: 

  • Suspected bladder cancer
  •  Gross/visible or microscopic hematuria
  •  Scheduled for cystoscopy

Not eligible if any of the following apply:

  • History of urinary tract malignancy
  • History of radiotherapy
  • Completed diagnostic assessments for bladder cancer

Kidney Study

Kidney Study

Kidney – Urinary Stone Treatment Study (NCT06942949)

Summary: Prospective trial of Enhanced Lithotripsy System (ELS) ultrasound treatment for patients with urinary stone present in ureter.

Requirements for participation: 

  • Single Ureteral stone within ureter (5-10 mm)
  • Ureteral stone visible on CT for measurement

Not eligible if any of the following apply:

  • Stones in both ureters
  • Ureteral stents
  • History of radiation therapy to pelvis/abdomen

Note to Study Participants

While qualified participants will not be paid for their participation, they will receive all study related medication, visits and tests at no cost depending on requirements of each study individually.